Apidra (Insulin Glulisine)
insulin glulisine
Indications for Insulin Glulisine
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 1 diabetes mellitus | Adults and pediatric patients ≥4 years | Mealtime insulin in basal-bolus regimen or CSII pump | FDA Approved |
| Type 2 diabetes mellitus | Adults | Mealtime insulin adjunctive to basal insulin and/or oral agents | FDA Approved |
Insulin glulisine received initial FDA approval in April 2004 as a rapid-acting human insulin analog. It differs from human insulin by two amino acid substitutions: asparagine at B3 is replaced by lysine, and lysine at B29 is replaced by glutamic acid. These changes promote rapid hexamer dissociation at the injection site, enabling faster absorption than regular human insulin. Insulin glulisine is equipotent to regular human insulin on a unit-for-unit basis. A key clinical advantage is its flexible meal timing — it may be administered within 15 minutes before a meal or within 20 minutes after starting a meal, making it uniquely suited for patients with unpredictable eating schedules. Pediatric use is supported by a 26-week non-inferiority trial vs insulin lispro in children ≥4 years with type 1 diabetes (FDA PI).
Diabetic ketoacidosis (DKA): Subcutaneous rapid-acting insulin analogs including glulisine have been used as alternatives to IV regular insulin in mild-to-moderate DKA. Evidence quality: Moderate (extrapolated from class data).
Gestational diabetes mellitus: Used when mealtime insulin is needed during pregnancy. Pharmacovigilance data and animal studies have not identified risk. Evidence quality: Moderate.
Hyperkalemia (IV): Combined with dextrose to drive potassium intracellularly. Evidence quality: Low (class effect).
Dosing of Insulin Glulisine
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T1DM — basal-bolus, mealtime coverage | Individualized; mealtime portion of TDD | By ICR and correction factor | No fixed ceiling | TDD typically 0.5–1 unit/kg/day Inject within 15 min before meal OR within 20 min after starting meal |
| T1DM — insulin pump (CSII) | Based on prior TDD; ~50% as basal rate | Programmed basal + meal boluses | No fixed ceiling | Reservoir change at least every 48 hours Do NOT dilute or mix in pump; do NOT exceed 98.6°F (37°C); abdominal wall only |
| T2DM — adding mealtime insulin to basal | 4 units or 10% of basal dose once daily at largest meal | Titrate by 1–2 units twice weekly | No fixed ceiling | Advance to additional meals as needed Concomitant oral antidiabetics may need adjustment |
| T2DM — full basal-bolus intensification | Divide mealtime insulin across 3 meals | Titrate per pre-meal and 2-h postprandial glucose | No fixed ceiling | TDD often 0.5–1.2 units/kg/day Post-meal dosing option useful for patients with erratic eating |
| IV insulin infusion (hospital) | Dilute to 0.05–1.0 unit/mL in 0.9% NaCl only | Per institutional protocol | Protocol-dependent | Use PVC infusion bags; stable 48 h at room temperature in NS NOT compatible with dextrose or Ringer’s solution |
Pediatric Dosing (≥4 Years, Type 1 Diabetes)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T1DM — mealtime coverage | Individualized | By ICR and correction factor | No fixed ceiling | Inject within 15 min before meal Non-inferiority to insulin lispro demonstrated in 26-week trial (n=572) |
Insulin glulisine is the only rapid-acting insulin analog with FDA-approved post-meal dosing (within 20 minutes after starting a meal). This is particularly valuable for patients with type 1 diabetes who have gastroparesis-related unpredictable meal absorption, elderly patients with variable appetite, or pediatric patients whose actual intake is uncertain at the time of injection. In a clinical trial, post-meal Apidra (given at meal start + 20 min) produced comparable HbA1c outcomes to pre-meal dosing. However, pre-meal administration remains preferred when feasible for optimal postprandial coverage (FDA PI).
Apidra may be mixed with NPH insulin for subcutaneous injection only. Draw insulin glulisine into the syringe first, then inject immediately after mixing. There is a 27% attenuation of Apidra Cmax when premixed with NPH, but Tmax is not affected. Do NOT mix Apidra with any other insulin or diluent when used in a pump or administered intravenously (FDA PI).
Pharmacology of Insulin Glulisine
Mechanism of Action
Insulin glulisine is a recombinant human insulin analog produced in Escherichia coli. It differs from human insulin by two amino acid substitutions: asparagine at position B3 is replaced by lysine, and lysine at position B29 is replaced by glutamic acid. These substitutions reduce the molecule’s tendency to form stable hexamers and promote rapid dissociation into monomers at the subcutaneous injection site, enabling faster absorption than regular human insulin. Once circulating, insulin glulisine binds to the insulin receptor with affinity comparable to native insulin, activating the PI3K/Akt signaling cascade. This stimulates GLUT4 translocation in skeletal muscle and adipose tissue, promotes glycogen synthesis, suppresses hepatic glucose output, and inhibits lipolysis and proteolysis. Insulin glulisine is equipotent to regular human insulin; one unit produces the same glucose-lowering effect as one unit of regular insulin (FDA PI).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Onset ~12–15 min; Tmax 60 min (median, range 40–120 min) at 0.15 U/kg; Cmax 83 µU/mL (vs 50 for regular insulin); bioavailability ~70% (abdomen 73%, deltoid 71%, thigh 68%); absorption independent of injection site | Faster onset than regular insulin; consistent bioavailability across injection sites eliminates need for site-specific dose adjustment; allows both pre-meal and post-meal dosing |
| Distribution | Vd 13 L (IV) vs 21 L for regular human insulin; low plasma protein binding | Smaller Vd may contribute to shorter duration of action; low protein binding means minimal displacement interactions |
| Metabolism | Degraded in liver, kidneys, and adipose tissue; identical pathway to endogenous insulin; no CYP involvement | In renal impairment (CrCl <50 mL/min), exposure increases 29–40% and clearance decreases 20–25%. Hepatic impairment not studied but monitor closely |
| Elimination | t½ 42 min (SC) vs 86 min for regular insulin; t½ 13 min (IV) vs 17 min for regular insulin; duration ~4–5 h | Shortest SC half-life among rapid-acting analogs (vs 81 min aspart, ~60 min lispro); faster elimination reduces late postprandial hypoglycemia risk |
Side Effects of Insulin Glulisine
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nasopharyngitis | 10.6% (T1DM); 7.6% (T2DM) | Background infection rate; comparable to comparator insulins in pooled trials |
| Upper respiratory tract infection | 6.6% (T1DM); 10.5% (T2DM) | Not considered causally related to insulin therapy; higher in T2DM population |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Severe symptomatic hypoglycemia (T1DM adults) | 4.8–8.4% | Requiring third-party assistance; rates comparable to lispro and regular insulin in trials |
| Peripheral edema | 7.5% (T2DM) | Insulin-mediated sodium retention; may exacerbate heart failure with TZDs |
| Influenza | 4.0–6.2% | Background infection rate in clinical trial populations |
| Arthralgia | 5.9% (T2DM) | Comparable to comparator (6.3%); not causally related to insulin |
| Injection site reactions | ~3% | Redness, swelling, itching; usually self-resolving; mitigated by site rotation |
| Weight gain | 1–5% | Anabolic effects of insulin; common to all insulin therapy |
| Allergic reactions (potential systemic) | 4.3% | vs 3.8% for comparator short-acting insulins; only 1/1833 discontinued due to allergy |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hypoglycemia | T1DM adults 4.8–8.4%; T2DM 1.4%; T1DM pediatric 16.2% (26 wk) | 30 min–5 h post-injection | Oral glucose, glucagon, or IV dextrose; assess precipitating factors |
| Hypoglycemic seizure (pediatric) | 6.1% (vs 4.7% lispro) | Variable | Emergency care; adjust dose; review carbohydrate intake |
| Anaphylaxis / severe allergic reaction | Rare | Minutes to hours after injection | Emergency treatment; permanent discontinuation |
| Hypokalemia | Uncommon (dose-related) | Hours after large doses | Monitor potassium; supplement as needed |
| Heart failure exacerbation (with TZDs) | Uncommon | Weeks to months | Monitor for fluid retention; reduce or stop TZD |
| DKA from pump malfunction | Uncommon | Hours after pump failure | Switch to SC injection; troubleshoot pump; monitor ketones |
In a 12-week CSII trial (n=59), catheter occlusion rates were 0.08/month with Apidra vs 0.15/month with insulin aspart, and infusion site reactions occurred in 10.3% vs 13.3%. Reservoir insulin must be changed at least every 48 hours (not 7 days as with some other rapid-acting analogs), reflecting stability characteristics specific to insulin glulisine in pump reservoirs. Patients must be trained to administer by injection and have backup supplies in case of pump failure (FDA PI).
Drug Interactions with Insulin Glulisine
Insulin glulisine is degraded proteolytically in the liver, kidneys, and adipose tissue with no CYP enzyme involvement. Drug interactions are pharmacodynamic, affecting glucose metabolism or masking hypoglycemia warning signs.
Monitoring for Insulin Glulisine
- Blood GlucosePre-meal, 2-h postprandial; per ADA targets
RoutineEssential for mealtime insulin titration. CGM recommended when available. ADA 2025 targets: pre-meal 80–130 mg/dL; 2-h postprandial <180 mg/dL. - HbA1cEvery 3 months until stable, then every 6 months
RoutineIn pivotal trials, HbA1c changes were comparable between Apidra and comparator rapid-acting insulins. - PotassiumWith IV use; periodically in at-risk patients
Trigger-basedAll insulins drive potassium intracellularly. Especially important during IV infusion and in patients on potassium-lowering medications. - Renal FunctionBaseline, then per ADA guidelines
RoutineExposure increases 29–40% in moderate-to-severe renal impairment (CrCl <50 mL/min). Dose reduction likely needed. - Injection / Infusion SitesEvery visit
RoutineInspect for lipodystrophy and cutaneous amyloidosis. Pump users: change infusion set per manufacturer instructions. - Pump FunctionContinuous (for CSII users)
RoutineChange reservoir at least every 48 hours. Pump failure requires immediate SC injection backup. Check pump compatibility before use. - WeightEvery visit
RoutineInsulin therapy promotes weight gain. Track trends and reinforce lifestyle counseling.
Contraindications & Cautions for Insulin Glulisine
Absolute Contraindications
- During episodes of hypoglycemia — do not administer while blood glucose is below normal range.
- Hypersensitivity to insulin glulisine or any excipient (metacresol, tromethamine, sodium chloride, polysorbate 20) — systemic allergic reactions have occurred.
Relative Contraindications (Specialist Input Recommended)
- Heart failure (NYHA III–IV) with TZDs — combination increases fluid retention risk.
- Hypoglycemia unawareness — requires CGM and potentially relaxed glycemic targets.
Use with Caution
- Renal impairment — exposure increases 29–40% with reduced clearance; dose reduction likely needed.
- Hepatic impairment — not studied; monitor closely due to potential for increased circulating insulin.
- Elderly patients (≥65 years) — use with caution; conservative dosing recommended.
- IV compatibility — Apidra is compatible ONLY with 0.9% NaCl (NS) for IV use; NOT compatible with dextrose or Ringer’s solution.
- Mixing insulins — may mix with NPH only (draw glulisine first); do NOT mix in pump or IV.
Accidental mix-ups between insulin products, particularly between long-acting and rapid-acting insulins, have been reported post-marketing. Patients must always verify the insulin label before each injection. Never share an Apidra SoloStar pen, syringe, or needle between patients, even if the needle is changed, due to blood-borne pathogen transmission risk (FDA PI).
Patient Counselling for Insulin Glulisine
Purpose of Therapy
Insulin glulisine (Apidra) is a fast-acting mealtime insulin that controls the rise in blood sugar when you eat. It works alongside a longer-acting basal insulin to manage your blood sugar throughout the day. A key advantage is that you can take it within 15 minutes before eating or within 20 minutes after you start eating, giving you more flexibility than some other mealtime insulins.
How to Take
Inject Apidra into the abdomen, thigh, or upper arm. Rotate injection sites. The solution should appear clear and colorless. Store unopened vials and pens in the refrigerator; once in use, store at room temperature (below 25°C / 77°F) for up to 28 days.
Sources
- Sanofi-Aventis. Apidra (insulin glulisine) injection, for subcutaneous or intravenous use. Full Prescribing Information. Bridgewater, NJ; Revised May 2025. Current PI (PDF)Primary regulatory reference for all dosing, indications, contraindications, adverse effects, and pharmacokinetic data.
- Sanofi-Aventis. Apidra (insulin glulisine) prescribing information. DailyMed/NLM. DailyMed LabelNLM-hosted current labeling with patient information and instructions for use.
- Sanofi-Aventis. Apidra (insulin glulisine) FDA label 2022 revision. FDA Label 2022 (PDF)Prior FDA label with complete PK data, clinical study tables, and renal impairment data.
- Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res. 2005;37(11):702-707. doi:10.1055/s-2005-870586Pivotal phase 3 trial (26 weeks) in T1DM comparing insulin glulisine with insulin lispro; demonstrated non-inferiority in HbA1c.
- Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(2):304-312. doi:10.1016/j.diabres.2006.09.032Key T2DM trial (26 weeks) demonstrating insulin glulisine non-inferiority to regular human insulin with comparable safety.
- Philotheou A, Arslanian S, Baekkeskov S, et al. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. Diabetes Technol Ther. 2011;13(3):327-334. doi:10.1089/dia.2010.0072Pediatric non-inferiority trial (n=572, age ≥4 years) supporting Apidra use in children with T1DM.
- American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S181-S206. doi:10.2337/dc25-S009Current ADA guidelines for mealtime insulin selection and management.
- Samson SL, Vellanki P, Blonde L, et al. AACE Comprehensive T2DM Management Algorithm—2023 Update. Endocr Pract. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001AACE algorithm for stepwise intensification with rapid-acting insulin analogs.
- Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother. 2005;6(4):643-651. doi:10.1517/14656566.6.4.643Review of the molecular modifications (B3 Lys, B29 Glu) that enable rapid hexamer dissociation and faster absorption.
- Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9(5):746-753. doi:10.1111/j.1463-1326.2007.00746.xHead-to-head PK/PD clamp study in obese subjects showing insulin glulisine has faster initial onset of action than insulin lispro.
- Becker RH, Frick AD, Burger F, et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers. Diabetes Technol Ther. 2005;7(1):150-159. doi:10.1089/dia.2005.7.150Steady-state PK study confirming faster absorption and shorter half-life (42 min SC) of insulin glulisine vs regular human insulin.
- Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47(1):7-20. doi:10.2165/00003088-200847010-00002Comprehensive PK review covering bioavailability (70%), renal impairment effects (exposure ↑29–40%), and injection site independence.
- Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, et al. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev. 2016;(1):CD011281. doi:10.1002/14651858.CD011281.pub2Cochrane review supporting SC rapid-acting insulin analogs for mild-to-moderate DKA.